Maria Teresa Schettino

Maria Teresa Schettino

Auto-generated profile, based on publicly available information

Maria Teresa Schettino

Department of Woman, Child and General and Specialized Surgery, University of Campania “Luigi Vanvitelli”, 80138 Naples, Italy

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 August 2009 in Molecular Medicine
Verified
Journal Article
Open access
AFAmalia Forte
Amalia Forte
MSMaria Teresa Schettino
Maria Teresa Schettino
MFMauro Finicelli
Mauro Finicelli
MCMarilena Cipollaro
Marilena Cipollaro
NCNicola Colacurci
Nicola Colacurci
Umberto GalderisiUmberto Galderisi
Umberto Galderisi
Endometriosis is a chronic disease characterized by the presence of ectopic endometrial tissue outside of the uterus with mixed traits of benign and malignant pathology. In this study we analyzed in endometrial and endometriotic tissues the differential expression of a panel of genes that are involved in preservation of stemness status and consequently considered as markers of stem cell presence. The expression profiles of a panel of 13 genes (SOX2, SOX15, ERAS, SALL4, OCT4, NANOG, UTF1, DPPA2, BMI1, GDF3, ZFP42, KLF4, TCL1) were analyzed by reverse transcription-polymerase chain reaction in human endometriotic (n = 12) and endometrial samples (n = 14). The expression of SALL4 and OCT4 was further analyzed by immunohistochemical methods. Genes UTF1, TCL1, and ZFP42 showed a trend for higher frequency of expression in endometriosis than in endometrium (P < 0.05 for UTF1), whereas GDF3 showed a higher frequency of expression in endometrial samples. Immunohistochemical analysis revealed that SALL4 was expressed in endometriotic samples but not in endometrium samples, despite the expression of the corresponding mRNA in both the sample groups. This study highlights a differential expression of stemness-related genes in ectopic and eutopic endometrium and suggests a possible role of SALL4-positive cells in the pathogenesis of endometriosis.

9 April 2022 in Medicina
Verified
Journal Article
Open access
PDF file
Matteo FrigerioMatteo Frigerio
Matteo Frigerio
Marta BarbaMarta Barba
Marta Barba
ACAlice Cola
Alice Cola
ABAndrea Braga
Andrea Braga
ACAngela Celardo
Angela Celardo
MTMarco Torella
Marco Torella
Urinary incontinence (UI) is a very common condition, negatively affecting social, occupational, domestic, and psychophysical wellbeing. In particular, a peculiar and detrimental effect of UI has been described concerning sexual function. However, the impact of UI on quality of life is not fully understood yet, and further investigation into this issue is warranted. With this narrative review, we aimed to report the current evidence from recent literature regarding the quality of life and psychological wellbeing in patients with urinary incontinence, with a special focus on sexual function and its evolution after UI treatment. There is strong evidence that urinary incontinence—in its different forms, including stress urinary incontinence, urge urinary incontinence, mixed urinary incontinence, and coital urinary incontinence—negatively affects female sexual function. Treatments aimed to cure urinary incontinence—including pelvic floor muscles training, medications, and surgery—seem to improve quality of life by recovering, at least in part, sexual function. In conclusion, there is a substantial association between involuntary urinary loss and sex life quality. However, few studies are available and more evidence is needed before consistent conclusions can be made.

23 October 2007 in Cell and tissue research
Verified
Journal Article
Closed access
PDF file
LCLuigi Cobellis
Luigi Cobellis
AMAnnunziata Mastrogiacomo
Annunziata Mastrogiacomo
EFElisabetta Federico
Elisabetta Federico
MSMaria Teresa Schettino
Maria Teresa Schettino
MFMaria De Falco
Maria De Falco
Antonio De LucaAntonio De Luca
Antonio De Luca

17 April 2022 in Medicina
Verified
Journal Article
Open access
PDF file
Vito Andrea CapozziVito Andrea Capozzi
Vito Andrea Capozzi
ESElisa Scarpelli
Elisa Scarpelli
GAGiulia Armano
Giulia Armano
LMLuciano Monfardini
Luciano Monfardini
ACAngela Celardo
Angela Celardo
SCStefano Cianci
Stefano Cianci
Background and Objectives: Since the Food and Drug Administration’s (FDA) approval in 2005, the application of robotic surgery (RS) in gynecology has been adopted all over the world. This study aimed to provide an update on RS in benign gynecological pathology by reporting the scientific recommendations and high-value scientific literature available to date. Materials and Methods: A systematic review of the literature was performed. Prospective randomized clinical trials (RCT) and large retrospective trials were included in the present review. Results: Twenty-two studies were considered eligible for the review: eight studies regarding robotic myomectomy, five studies on robotic hysterectomy, five studies about RS in endometriosis treatment, and four studies on robotic pelvic organ prolapse (POP) treatment. Overall, 12 RCT and 10 retrospective studies were included in the analysis. In total 269,728 patients were enrolled, 1721 in the myomectomy group, 265,100 in the hysterectomy group, 1527 in the endometriosis surgical treatment group, and 1380 patients received treatment for POP. Conclusions: Currently, a minimally invasive approach is suggested in benign gynecological pathologies. According to the available evidence, RS has comparable clinical outcomes compared to laparoscopy (LPS). RS allowed a growing number of patients to gain access to MIS and benefit from a minimally invasive treatment, due to a flattened learning curve and enhanced dexterity and visualization.

28 June 2022 in Medicina
Verified
Journal Article
Open access
PDF file
BGBarbara Gardella
Barbara Gardella
AGAndrea Gritti
Andrea Gritti
ESEhsan Soleymaninejadian
Ehsan Soleymaninejadian
MPMarianna Francesca Pasquali
Marianna Francesca Pasquali
GRGaetano Riemma
Gaetano Riemma
MDMattia Dominoni
Mattia Dominoni
Human Papillomavirus is the main cause of cervical cancer, including squamous cell carcinoma of the oropharynx, anus, rectum, penis, vagina, and vulva. In recent years, considerable effort has been made to control HPV-induced diseases using either prophylactic or therapeutic approaches. A critical review of the literature about the therapeutic Human Papillomavirus vaccine was performed to analyze its efficacy in the treatment of female lower genital tract lesions and its possible perspective application in clinical practice. The most important medical databases were consulted, and all papers published from 2000 until 2021 were considered. We retrieved a group of seven papers, reporting the role of anti HPV therapeutic vaccines against the L2 protein in the order of their efficacy and safety in female lower genital tract disease. In addition, the immune response due to vaccine administration was evaluated. The development of therapeutic vaccines represents an interesting challenge for the treatment of HPV infection of the lower genital tract. Literature data underline that the L2 protein may be an interesting and promising target in the development of therapeutic HPV vaccines, but the possible strengths and the unclear longevity of L2 immune responses are factors to be considered before clinical use.

1 January 2013 in Journal of Infection and Chemotherapy
Verified
Journal Article
Closed access
MTMarco Torella
Marco Torella
MSMaria Teresa Schettino
Maria Teresa Schettino
PFPasquale De Franciscis
Pasquale De Franciscis
NCNicola Colacurci
Nicola Colacurci
SSStefano Salvatore
Stefano Salvatore
Maurizio SeratiMaurizio Serati
Maurizio Serati